Faust Pharmaceuticals has completed a Phase IIa clinical trial of its lead molecule, FP0011, in amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). The results observed in patients showed the antiglutamatergic drug was safe and well-tolerated,

The goal of the trial was to acquire data on FP0011 patient tolerance and safety, and to check whether it was possible to administer FP0011 in combination with riluzole, currently the only ALS treatment on the market. The trial showed that FP0011, administered for one month at the doses of 60 and 120mg per day, did not modify plasma concentrations of riluzole, and displayed an excellent clinical and biological safety.